Xenikos B.V.
BioTech/Drugs - N/A, N/A, NL
Xenikos B.V. Details
Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company's lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
Xenikos B.V. Technologies
Email Providers
Outlook
Load Balancers
Apache
Fonts
Google Font API
Other
Mobile Friendly